GLP-1 FDA approval status and approved indications statistics

FDA approval is tied to the product and use

GLP-1 means glucagon-like peptide-1. A GLP-1 receptor agonist acts like a gut hormone involved in insulin release, appetite, and digestion. Tirzepatide also acts on the glucose-dependent insulinotropic polypeptide, or GIP, receptor, so it is described as a dual GIP/GLP-1 medicine. The active ingredient alone does not establish the approved use. Ozempic, Rybelsus, and Wegovy contain semaglutide, but their labels differ. Mounjaro and Zepbound contain tirzepatide, yet Mounjaro is approved for type 2 diabetes and Zepbound is approved for chronic weight management and, in qualifying adults with obesity, moderate-to-severe obstructive sleep apnea. Wegovy injection has the broadest set of listed uses in this group. Its label includes chronic weight management, reduced risk of major adverse cardiovascular events, or MACE, in eligible adults, and adults with noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, with F2 to F3 fibrosis. MACE usually means cardiovascular death, nonfatal heart attack, or nonfatal stroke.

The approval timeline explains why labels now differ

The first FDA-approved GLP-1 medicine, Byetta, arrived in 2005 for type 2 diabetes. Chronic weight management entered the timeline with Saxenda in 2014, followed by Wegovy injection in 2021 and Zepbound in 2023. Recent changes affect access conversations because they add approved non-weight uses. Wegovy received a cardiovascular-risk expansion on March 8, 2024, an accelerated-approval MASH indication on August 15, 2025, and later tablet and higher-dose injection forms. Zepbound's sleep-apnea approval arrived on December 20, 2024. Foundayo, orforglipron, was approved on April 1, 2026 for adult chronic weight management. It is a daily GLP-1 pill, but FDA has not approved it for diabetes, cardiovascular-risk reduction, sleep apnea, or MASH. A pill routine may be appealing, but it does not make products interchangeable.

Expected weight results need a timeframe

Controlled trials give useful averages, not promises. They include structured follow-up, gradual dose increases, and lifestyle support that may differ from day-to-day care. Health conditions, tolerability, missed doses, affordability, and whether treatment continues can all change an individual's result. In STEP 1, adults without diabetes using weekly semaglutide 2.4 mg lost an average 14.9% of starting weight at week 68. At a 250-pound starting weight, that is about 37 pounds on average. In SURMOUNT-1, tirzepatide 15 mg averaged 20.9% at week 72, roughly 52 pounds from 250 pounds. Foundayo 17.2 mg averaged 11.1% at 72 weeks among adults without diabetes and 9.6% among adults with type 2 diabetes. That is about 28 pounds and 24 pounds, respectively, from 250 pounds. These are separate studies, so the figures are not a head-to-head test and should not be used as a personal forecast.

MASH results measure liver response rather than pounds

MASH is metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease that can involve inflammation and scarring. For Wegovy's MASH indication, the main study results are biopsy outcomes. At week 72, 63% of people taking Wegovy had MASH resolution without worsening fibrosis, compared with 34% taking placebo. Fibrosis improved without worsening MASH in 37% with Wegovy and 22% with placebo. FDA granted accelerated approval, which allows approval based on a surrogate endpoint while a required trial continues to confirm clinical benefit such as fewer liver-related events, transplants, or deaths. This indication is for adults with noncirrhotic MASH and F2 to F3 fibrosis, not for every person with fatty liver.

Coverage and price are separate questions

FDA approval does not require an insurer to pay. Commercial plans may require prior authorization, a qualifying diagnosis, body-mass-index documentation, or use of another product first. Call the plan or check its formulary for the exact brand and formulation, because a decision for Wegovy injection may not answer the question for Wegovy tablets or Wegovy HD. Medicare Part D can cover GLP-1 medicines for covered uses other than weight management, such as type 2 diabetes and certain labeled cardiovascular, MASH, or sleep-apnea uses. On July 1, 2026, CMS started the Medicare GLP-1 Bridge for eligible Part D enrollees using specified products for weight management. It has a $50 monthly copay and is scheduled through December 31, 2027. Published manufacturer figures are starting points, not a promise of your pharmacy bill. A deductible, coinsurance, savings-card eligibility, dose, and the dispensing channel can change what you pay. The Bridge's $245 monthly manufacturer net-price figure is a program payment figure, not a usual retail cash price.

Safety and routine questions to bring to the pharmacy

Nausea, diarrhea, vomiting, constipation, stomach pain, reduced appetite, and other digestive symptoms are common with these medicines. Symptoms can be more noticeable while a dose is being increased. Severe or persistent symptoms deserve prompt discussion with the prescribing clinician or pharmacist. Labels also contain warnings or precautions about pancreatitis, gallbladder disease, dehydration-related kidney injury, low blood sugar when used with insulin or certain diabetes drugs, and delayed stomach emptying. Most products carry a boxed warning about thyroid C-cell tumors seen in rodents. They should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; the relevance of the rodent finding in humans is unknown. Compounded semaglutide or tirzepatide is not FDA-approved in the way branded products are. FDA has warned about dosing errors, salt forms, quality concerns, and adverse events involving some compounded GLP-1 products. National shortages of semaglutide and tirzepatide injections have been resolved, so a lower price alone is not evidence that a compounded vial is equivalent or appropriate.

Maintenance deserves a plan before a stop or restart

Weight-management labels describe long-term reduction and maintenance. When treatment stops, appetite effects can fade and weight regain is common. That pattern does not mean someone has failed; it means stopping is a health and practical decision that benefits from a follow-up plan. A conversation about continuing, pausing, restarting, or changing a product can cover side effects, affordability, nutrition, movement, muscle preservation, pregnancy plans, surgery, other medicines, and the condition being treated. Do not assume a change between brands, tablets, injections, or compounded products is a milligram-for-milligram substitution. Bring the exact product name, formulation, start date, recent refill history, plan name, and pharmacy costs to a visit. Tracking symptoms, food and fluid intake, weight when useful, sleep, movement, blood glucose if you monitor it, and refill barriers can make a medical or financial problem easier to identify. Lina is a GLP-1 companion app for people using Wegovy, Mounjaro, Ozempic, Zepbound, Saxenda, and related medications. It helps users track doses, side effects, meals, weight, protein, hydration, and habits in one place.